WO2010074992A3 - Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders - Google Patents

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders Download PDF

Info

Publication number
WO2010074992A3
WO2010074992A3 PCT/US2009/067552 US2009067552W WO2010074992A3 WO 2010074992 A3 WO2010074992 A3 WO 2010074992A3 US 2009067552 W US2009067552 W US 2009067552W WO 2010074992 A3 WO2010074992 A3 WO 2010074992A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
controlled release
sensory cell
compositions
Prior art date
Application number
PCT/US2009/067552
Other languages
French (fr)
Other versions
WO2010074992A2 (en
Inventor
Jay Lichter
Benedikt Vollrath
Andrew M. Trammel
Sergio G. DURÓN
Fabrice Piu
Luis A. Dellamary
Qiang Ye
Carl Lebel
Michael Christopher Scaife
Jeffrey P. Harris
Original Assignee
Otonomy, Inc.
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0907070A external-priority patent/GB2461962B/en
Priority claimed from US12/504,553 external-priority patent/US8496957B2/en
Application filed by Otonomy, Inc., The Regents Of The University Of California filed Critical Otonomy, Inc.
Priority to JP2011542272A priority Critical patent/JP6013736B2/en
Priority to AU2009330458A priority patent/AU2009330458B2/en
Priority to CN2009801305625A priority patent/CN102112111A/en
Priority to CA2732686A priority patent/CA2732686C/en
Priority to EP09835529.0A priority patent/EP2299976A4/en
Publication of WO2010074992A2 publication Critical patent/WO2010074992A2/en
Publication of WO2010074992A3 publication Critical patent/WO2010074992A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with auris sensory cell modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
PCT/US2009/067552 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders WO2010074992A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2011542272A JP6013736B2 (en) 2008-12-22 2009-12-10 Controlled release of an ear sensory cell modulator composition for the treatment of otic disorders and methods thereof
AU2009330458A AU2009330458B2 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN2009801305625A CN102112111A (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CA2732686A CA2732686C (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP09835529.0A EP2299976A4 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US14003308P 2008-12-22 2008-12-22
US61/140,033 2008-12-22
US16023309P 2009-03-13 2009-03-13
US61/160,233 2009-03-13
US16481209P 2009-03-30 2009-03-30
US61/164,812 2009-03-30
GB0907070A GB2461962B (en) 2008-07-25 2009-04-24 Slow release NMDA receptor antagonist for otic disorders
GB0907070.7 2009-04-24
US17442109P 2009-04-30 2009-04-30
US61/174,421 2009-04-30
US12/504,553 US8496957B2 (en) 2008-07-21 2009-07-16 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US12/504,553 2009-07-16

Publications (2)

Publication Number Publication Date
WO2010074992A2 WO2010074992A2 (en) 2010-07-01
WO2010074992A3 true WO2010074992A3 (en) 2010-10-21

Family

ID=42288363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/067552 WO2010074992A2 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Country Status (6)

Country Link
EP (1) EP2299976A4 (en)
JP (4) JP6013736B2 (en)
CN (2) CN102112111A (en)
AU (1) AU2009330458B2 (en)
CA (1) CA2732686C (en)
WO (1) WO2010074992A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013123298A1 (en) 2012-02-17 2013-08-22 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
AU2015296616A1 (en) * 2014-07-29 2017-03-02 Otonomy, Inc. Otic formulations for the treatment of ceruminosis
CR20180128A (en) 2015-08-05 2018-04-24 Childrens Medical Center COMPOSITIONS WITH PERMEATION POTENTIALS FOR DRUG SUPPLY
US20200261417A1 (en) 2016-05-18 2020-08-20 Sound Pharmaceuticals Incorporated Treatment of meniere's disease
US20200138710A1 (en) * 2016-09-14 2020-05-07 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
KR20190060786A (en) * 2016-09-16 2019-06-03 바이킹 테라퓨틱스 인코포레이티드 How to Reduce Thyroid-Related Side Effects
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. Method of treating glycogen storage disease
WO2018112815A1 (en) * 2016-12-22 2018-06-28 Nanjing University Animal model for hearing loss syndrome and treatment method thereof
CA3064940A1 (en) 2017-06-05 2018-12-13 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
JP2021518403A (en) 2018-03-22 2021-08-02 バイキング・セラピューティクス・インコーポレイテッド Crystal form of compound and method of producing crystal form of compound
JPWO2020045162A1 (en) * 2018-08-30 2021-08-12 学校法人慶應義塾 Carrier for drug delivery

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US20030092776A1 (en) * 1998-08-04 2003-05-15 Ron Eyal S. End modified thermal responsive hydrogels
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
CA2497867A1 (en) * 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US7589110B2 (en) * 2002-09-06 2009-09-15 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
JP2005220070A (en) * 2004-02-05 2005-08-18 Medgel Corp Bioabsorbable polymer hydrogel preparation for neurotization and neuroprotection
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP2006111585A (en) * 2004-10-15 2006-04-27 Mebiol Kk Sustained release composition and sustained releasing method therefor
US20060205789A1 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Gacyclidine formulations
CU20080044A7 (en) * 2005-09-28 2011-04-26 Pharmaceutical compositions for the treatment of disorders of the inner ear.
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
AU2009239429B2 (en) * 2008-04-21 2013-08-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
JP5551685B2 (en) * 2008-05-14 2014-07-16 オトノミ―，インク． Controlled release corticosteroid compositions and methods of treating otic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US20030092776A1 (en) * 1998-08-04 2003-05-15 Ron Eyal S. End modified thermal responsive hydrogels
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2299976A4 *

Also Published As

Publication number Publication date
CA2732686A1 (en) 2010-07-01
JP2012513394A (en) 2012-06-14
AU2009330458B2 (en) 2013-08-22
JP2018138585A (en) 2018-09-06
JP2015164943A (en) 2015-09-17
CA2732686C (en) 2017-10-03
JP6013736B2 (en) 2016-10-25
EP2299976A4 (en) 2014-07-23
AU2009330458A1 (en) 2010-07-01
EP2299976A2 (en) 2011-03-30
CN106344495A (en) 2017-01-25
JP6207093B2 (en) 2017-10-04
WO2010074992A2 (en) 2010-07-01
CN102112111A (en) 2011-06-29
JP2017160232A (en) 2017-09-14

Similar Documents

Publication Publication Date Title
WO2010074992A3 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010008995A3 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
WO2010011466A3 (en) Controlled-release cns modulating compositions and methods for the treatment of otic disorders
WO2011050206A3 (en) Compositions and methods for the treatment of sinonasal disorders
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
WO2010011605A3 (en) Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
WO2009132050A3 (en) Auris formulations for treating otic diseases and conditions
WO2009139924A3 (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2010068281A3 (en) Contact lens drug delivery device
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
WO2012027065A3 (en) Combination therapy for treatment of disease
MX2018015635A (en) Compositions and methods for modulation of smn2 splicing in a subject.
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
EA202091999A3 (en) APPLICATION OF DPP IV INHIBITORS
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
WO2005071080A3 (en) Modulation of glucocorticoid receptor expression
MX2016002408A (en) Treatment of pediatric otic disorders.
CO6311060A2 (en) INTRAUTERINE SYSTEM TO SUPPLY A SUBSTANCE OR THERAPEUTIC PRODUCT DIRECTLY WITHIN THE UTERUS OF A PATIENT AND METHOD FOR MANUFACTURING
EP2358378A4 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2013052647A3 (en) Formulations and uses of retinoic acid receptor selective agonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980130562.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835529

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009835529

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009330458

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 637/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2011542272

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2732686

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009330458

Country of ref document: AU

Date of ref document: 20091210

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE